| The international consensus classification of mature lymphoid neoplasms: a report from the clinical advisory committee E Campo, ES Jaffe, JR Cook, L Quintanilla-Martinez, SH Swerdlow, ... Blood, The Journal of the American Society of Hematology 140 (11), 1229-1253, 2022 | 654 | 2022 |
| High-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements with diffuse large B-cell lymphoma morphology DW Scott, RL King, AM Staiger, S Ben-Neriah, A Jiang, H Horn, A Mottok, ... Blood, The Journal of the American Society of Hematology 131 (18), 2060-2064, 2018 | 224 | 2018 |
| Diagnosis and management of Waldenström macroglobulinemia: Mayo stratification of macroglobulinemia and risk-adapted therapy (mSMART) guidelines 2016 P Kapoor, SM Ansell, R Fonseca, A Chanan-Khan, RA Kyle, SK Kumar, ... JAMA oncology 3 (9), 1257-1265, 2017 | 138 | 2017 |
| Routine cerebrospinal fluid enterovirus polymerase chain reaction testing reduces hospitalization and antibiotic use for infants 90 days of age or younger RL King, SA Lorch, DM Cohen, RL Hodinka, KA Cohn, SS Shah Pediatrics 120 (3), 489-496, 2007 | 126 | 2007 |
| Morphologic features of ALK-negative anaplastic large cell lymphomas with DUSP22 rearrangements RL King, LN Dao, ED McPhail, ES Jaffe, J Said, SH Swerdlow, CA Sattler, ... The American journal of surgical pathology 40 (1), 36-43, 2016 | 117 | 2016 |
| Addition of lenalidomide to R-CHOP improves outcomes in newly diagnosed diffuse large B-cell lymphoma in a randomized phase II US intergroup study ECOG-ACRIN E1412 GS Nowakowski, F Hong, DW Scott, WR Macon, RL King, TM Habermann, ... Journal of Clinical Oncology 39 (12), 1329, 2021 | 94 | 2021 |
| Bendamustine and rituximab (BR) versus dexamethasone, rituximab, and cyclophosphamide (DRC) in patients with Waldenström macroglobulinemia J Paludo, JP Abeykoon, A Shreders, SM Ansell, S Kumar, S Ailawadhi, ... Annals of hematology 97, 1417-1425, 2018 | 86 | 2018 |
| Predictors of survival in refractory anemia with ring sideroblasts and thrombocytosis (RARS‐T) and the role of next‐generation sequencing MM Patnaik, TL Lasho, CM Finke, CA Hanson, RL King, RP Ketterling, ... American journal of hematology 91 (5), 492-498, 2016 | 82 | 2016 |
| Genomic profiling for clinical decision making in lymphoid neoplasms L De Leval, AA Alizadeh, PL Bergsagel, E Campo, A Davies, A Dogan, ... Blood, The Journal of the American Society of Hematology 140 (21), 2193-2227, 2022 | 74 | 2022 |
| Lymphomas arising in immune-privileged sites: insights into biology, diagnosis, and pathogenesis RL King, JR Goodlad, M Calaminici, S Dotlic, S Montes-Moreno, ... Virchows Archiv 476, 647-665, 2020 | 74 | 2020 |
| Biology and prognostic impact of clonal plasmacytoid dendritic cells in chronic myelomonocytic leukemia N Lucas, M Duchmann, P Rameau, F Noël, P Michea, V Saada, ... Leukemia 33 (10), 2466-2480, 2019 | 71 | 2019 |
| MYD88 mutation status does not impact overall survival in Waldenström macroglobulinemia JP Abeykoon, J Paludo, RL King, SM Ansell, MA Gertz, BR LaPlant, ... American journal of hematology 93 (2), 187-194, 2018 | 67 | 2018 |
| Safety and accuracy of percutaneous image-guided core biopsy of the spleen MC Olson, TD Atwell, WS Harmsen, A Konrad, RL King, Y Lin, DJ Wall American Journal of Roentgenology 206 (3), 655-659, 2016 | 67 | 2016 |
| Kidney involvement of patients with Waldenström macroglobulinemia and other IgM-producing B cell lymphoproliferative disorders L Higgins, SH Nasr, SM Said, P Kapoor, D Dingli, RL King, SV Rajkumar, ... Clinical Journal of the American Society of Nephrology 13 (7), 1037-1046, 2018 | 62 | 2018 |
| Late relapses in patients with diffuse large B-cell lymphoma treated with immunochemotherapy Y Wang, U Farooq, BK Link, MC Larson, RL King, MJ Maurer, C Allmer, ... Journal of clinical oncology 37 (21), 1819, 2019 | 61 | 2019 |
| Lymphoplasmacytic Lymphoma With a Non-IgM Paraprotein Shows Clinical and Pathologic Heterogeneity and May Harbor MYD88 L265P Mutations RL King, WI Gonsalves, SM Ansell, PT Greipp, LA Frederick, ... American journal of clinical pathology 145 (6), 843-851, 2016 | 57 | 2016 |
| Methionine aminopeptidase 2 inhibition is an effective treatment strategy for neuroblastoma in preclinical models MJ Morowitz, R Barr, Q Wang, R King, N Rhodin, B Pawel, H Zhao, ... Clinical cancer research 11 (7), 2680-2685, 2005 | 52 | 2005 |
| Myeloid/Lymphoid Neoplasms Associated With Eosinophilia and Rearrangements of PDGFRA, PDGFRB, or FGFR1 or With PCM1-JAK2 O Pozdnyakova, A Orazi, K Kelemen, R King, KK Reichard, FE Craig, ... American journal of clinical pathology 155 (2), 160-178, 2021 | 51 | 2021 |
| IMP-3 is differentially expressed in normal and neoplastic lymphoid tissue RL King, T Pasha, MR Roullet, PJ Zhang, A Bagg Human pathology 40 (12), 1699-1705, 2009 | 51 | 2009 |
| IgM AL amyloidosis: delineating disease biology and outcomes with clinical, genomic and bone marrow morphological features S Sidana, DP Larson, PT Greipp, R He, ED McPhail, A Dispenzieri, ... Leukemia 34 (5), 1373-1382, 2020 | 50 | 2020 |
